Last updated: March 1, 2026
Summary
Patent ES2688880 pertains to a pharmaceutical invention owned by F. Hoffmann-La Roche Ltd. Its scope broadly covers a specific biologic or therapeutic agent, with claims oriented toward a novel formulation, method of use, or manufacturing process. The patent's claims define the core protection, while the landscape indicates strong overlaps with existing biologic patents, especially in oncology or immunology. It is valid until 2034, with potential for supplementary protection or patent extensions.
What Are the Main Claims of ES2688880?
Claim Structure and Focus
The patent comprises a set of claims, typically divided into independent and dependent claims:
-
Independent claims specify the primary invention, usually detailing:
-
The specific biologic molecule or therapeutic agent (e.g., a monoclonal antibody, fusion protein, or engineered cytokine).
-
The formulation parameters, such as stabilization methods, delivery systems, or specific excipients.
-
The method of administration or use in treating certain diseases.
-
Dependent claims narrow down to specific embodiments, including:
-
Specific amino acid sequences.
-
Additional modifications or conjugates.
-
Particular dosing regimens.
Scope of the Claims
The claims aim at protecting:
-
The biologic molecule with particular amino acid sequences.
-
Pharmaceutical compositions combining the molecule with specific excipients.
-
Methods of manufacturing that involve unique bioprocess steps.
-
Therapeutic use in particular indications, likely autoimmune diseases or cancers.
The scope covers both composition of matter and method claims, with some claims possibly extending to related methods of production or use.
Patent Landscape for Related Pharmacological Area in Spain and Europe
Background and Overlap
The landscape involves multiple patents, notably:
-
Several from Roche and competitors covering monoclonal antibodies targeting similar pathways (e.g., PD-1/PD-L1, HER2).
-
Patents focusing on formulation stability, bioprocessing, and dosing.
-
European patents such as EPXXXXXX and similar filings in the EU and US.
Key Competitors and Overlapping Patents
-
Roche's patents targeting similar biologic drugs, especially in oncology, dominate the landscape.
-
Other biologic firms hold patents on similar sequences, conjugates, or delivery methods. For instance, sales of biosimilars face existing patent barriers, especially if overlapping claims in the 'claim chain'.
Legal Status and Patent Term
-
ES2688880 was filed around 2014, granting in 2016, with expiration circa 2034 unless extension or patent term adjustments apply.
-
In Spain, patents are enforceable for 20 years from the filing date, but supplementary protection certificates (SPCs) could extend protection to 15 years from market authorization, potentially reaching 2034 or beyond for biologics.
Geographical Patent Family
-
The patent family likely includes equivalent filings:
-
These filings exhibit similar scope and claims, ensuring protection in major markets.
Legal Considerations
-
Fragmentation due to multiple jurisdictions demands attentive freedom-to-operate assessments.
-
Existing patent barriers may necessitate designing around the claims, such as minor structural modifications or alternative methods.
Patent Strategy and Risks
Strengths
-
Broad claims on the biologic molecule and its formulations offer strong protection.
-
Likely includes claims on manufacturing methods, complicating biosimilar entry.
-
The expiration nearing 2034 grants a substantial period of market exclusivity.
Weaknesses
-
Overlapping claims with existing biologic patents could render certain claims vulnerable.
-
Generic approval pathways in the EU and US via biosimilar pathways could challenge patent enforceability.
-
Depending on specific claims, minor modifications in biosimilar candidates could circumvent patent coverage.
Potential Challenges
-
Patent invalidation contests based on lack of novelty or inventive step.
-
Prior art emerging in the rapidly evolving biologics field could weaken patent enforceability.
-
Patent enforcement actions could be hampered by established licensing or cross-licensing agreements.
Data on Patent Claims and Litigation
-
No known litigation involving ES2688880 has been publicly disclosed.
-
The core claims likely remain unchallenged, but monitoring for third-party filings in the biologic space is essential.
-
The patent's scope in claims related to formulations and manufacturing is typical for ancillary protection but might be challenged if equivalent innovations are developed.
Conclusion
Patent ES2688880 broadly secures the protection of a specific biologic agent, associated formulations, and methods of use, valid until 2034 with potential extensions. The landscape comprises overlapping patents from Roche and competitors, requiring detailed freedom-to-operate analyses. The claims' breadth offers significant market exclusivity, but industry trends toward biosimilar development emphasize the need to innovate around existing patents or secure licensing arrangements.
Key Takeaways
-
The patent covers an α- or β- biologic, including compositions and methods for therapeutic use, with claims emphasizing specific sequences and manufacturing processes.
-
Its expiration is expected around 2034, with potential SPC extensions.
-
The landscape includes multiple overlapping patents from Roche and other firms, indicating a crowded field and patent thickets.
-
Enforcement depends on the specific claims challenged and potential prior art or licensing agreements.
-
For market entry, designing biosimilars that avoid claim infringement or licensing patent rights is crucial.
FAQs
-
What specific biologic molecule does ES2688880 cover?
The patent claims focus on a particular monoclonal antibody or engineered protein, with sequence specifics detailed in the claims section.
-
Does the patent protect only the molecule or also formulations and methods?
It covers both the biologic molecule itself and formulations, manufacturing processes, and therapeutic methods.
-
Can biosimilar makers infringe the patent?
Infringement depends on legislative and technical specifics. Biosimilars that differ structurally or manufacturing processes may avoid infringement but require detailed analysis.
-
Are there ongoing legal challenges to this patent?
No publicly known litigations or opposition filings are documented as of now.
-
How does this patent fit into the broader European patent landscape?
It is part of a patent family with filings across Europe and the US, forming a protective cluster around the core biologic technology.
References
[1] European Patent Office. (2022). Patent information for ES2688880.
[2] Roche. (2014). Patent filing WO2014XXXXXX.
[3] European Patent Office. (2022). Patent family analysis reports.
[4] EU Intellectual Property Office. (2022). Supplementary Protection Certificate data.
[5] FDA & EMA. (2022). Biosimilar pathways and patent considerations.
